FirsthandHealth
medRxiv PreprintsInternational20 November 2026

Plasma neurodegeneration biomarkers and clinical progression in early sporadic Parkinson's disease

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Objectives: Plasma neurodegeneration biomarkers offer an opportunity to characterize Parkinson's disease (PD) biology. The objective of this study was to investigate such biomarkers in deeply-phenotyped participants in Parkinson's Precision Medicine Initiative (PPMI). Methods: Baseline plasma samples from early (<2 years since diagnosis) sporadic PD participants with a positive CSF alpha-synuclein seed amplification assay (aSyn-SAA) and healthy controls (HC) with a negative aSyn-SAA test were utilized. Plasma P-tau217 (Roche Diagnostics), neurofilament light chain (NfL, Quanterix), glial fibri
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.